Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

ogram for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of its technology platform, the potential of NKTR-102 for breast cancer patients, preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the Phase 2 data for NKTR-102 in breast cancer in this press release remain subject to audit and confirmation procedures, and the final results may change materially and adversely after such procedures are completed; (iii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in metastatic breast cancer including but not limited to final progression-free survival and overall survival and therefore the complete and final results for this study may diff
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... 22, 2014  CryoLife, Inc. (NYSE: CRY ... focused on cardiac and vascular surgery, announced today that ... Executive Officer, has been elected to the Company,s Board ... Steven G. Anderson , Executive Chairman of CryoLife, stated, "Since ... be an excellent leader who is well positioned to ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... control versus Concerta from 30 minutes to six hours post-dose in ... as 30 minutes post-dose, - Additional analysis suggests Focalin XR provides comparable efficacy ... Concerta ... impact a child,s ability to focus and learn in an educational ...
... ANA773 Acting via ... ... July 7 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today ... for the,treatment of chronic hepatitis C. Based on preclinical pharmacology testing,and ...
Cached Medicine Technology:Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 2Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 3Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 4Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 5Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 6Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 7Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 8Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival ... (Alimta), after his combination drug therapy became too toxic. ... just posted on the Surviving Mesothelioma website. , ... in Japan suggests that “maintenance therapy” with pemetrexed may ... cannot tolerate higher doses of cisplatin. , “Although ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
(Date:10/22/2014)... 2014 At a time when the ... and athletes at all levels, the UPMC Sports ... current discussion where two powerful messages are lost: Concussions ... result in full recoveries every day. , In striving ... fact and research, UPMC and the Concussion Program are ...
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... Vietnam Veteran Regain Mobility and Independence , , ... never stopped Anthony Radonski. He has survived the rain forests of ... has tested the 60-year-old war hero,s spirit like nothing else -- ... to him. , , ...
... BATESVILLE, Ind., Nov. 20 Hill-Rom (NYSE: ... technologies and,related services for the health care industry, today ... gold award for excellence in the Best,Custom Content category. ... annually by Brandon Hall Research, one of the leading ...
... N.J.,Nov. 20 MedQuist Inc. (Nasdaq: MEDQ ) ... analytics applications for radiology, today announced a cooperative agreement to ... recognition solution, SpeechQ for Radiology(TM). The companies will be demonstrating ... 30-Dec. 4 in Chicago): , , ...
... provides solution to surveying physicians and pharmacists in U.S. and Europe ... ... -- Market research firms seeking to conduct healthcare surveys internationally can ... source. The company announced today that its market research panel has ...
... 20 Unemployment continues to,grow nationwide, with more layoffs happening ... laid off -- the ones now doing their own,jobs as ... a problem costing businesses productivity and profits, and Scent To ... something,about it. , Just ...
... Forward Expeditions LLC, Ely, Minn.,announced today that ... North,Pole expedition to raise awareness and funds ... personalized Web sites to,people facing serious medical ... CaringBridge connects more than 20 million families ...
Cached Medicine News:Health News:The SCOOTER Store Donates Power Wheelchair to California War Hero, a Purple Heart Recipient 2Health News:The SCOOTER Store Donates Power Wheelchair to California War Hero, a Purple Heart Recipient 3Health News:Hill-Rom Wins Gold Brandon Hall Learning Award 2Health News:MedQuist and Primordial to Demonstrate Integrated Applications at RSNA 2Health News:MedQuist and Primordial to Demonstrate Integrated Applications at RSNA 3Health News:Epocrates Offers International Market Research Panel 2Health News:Scent To Sleep Offers Help for Companies Losing Time, Money to Microsleep 2Health News:Forward Expeditions to Promote CaringBridge(R) on Historic Victorinox North Pole '09 Expedition 2Health News:Forward Expeditions to Promote CaringBridge(R) on Historic Victorinox North Pole '09 Expedition 3Health News:Forward Expeditions to Promote CaringBridge(R) on Historic Victorinox North Pole '09 Expedition 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: